HC Wainwright & Co. Reiterates Buy on Phathom Pharmaceuticals, Maintains $28 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a price target of $28.
August 12, 2024 | 10:00 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Phathom Pharmaceuticals (NASDAQ:PHAT) and maintained a price target of $28.
The reiteration of a Buy rating and maintenance of a $28 price target by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100